Introduction
Plaque psoriasis is a chronic, inflammatory, autoimmune disorder that is thought to be due to an increased flux of leukocyte, specifically T-cells, to the dermis and epidermis. This influx induces increased cytokine production, altering the epidermal skin-cell cycle, and causing the skin to shed more frequently, 1 resulting in raised patches of dead skin -the psoriatic plaques. 1, 2 Because of the primary role of T-cells in the pathology of psoriasis, biologic agents have been developed to target these cells and their functions. 3, 4 There are three monoclonal antibodies (adalimumab, infliximab and ustekinumab) and two circulating receptor fusion proteins (alefacept and etanercept) available for the treatment of plaque psoriasis in the United Kingdom and the United States.
To the authors' knowledge, there have been no randomized controlled trials (RCTs) comparing all available biologic therapies, and the authors have used meta-analytic techniques to estimate the comparative efficacy and safety of these agents. [5] [6] [7] [8] [9] [10] [11] Three meta-analyses [10] [11] [12] did not include ustekinumab and three 5, 6, 9 provided results of pairwise comparisons of active treatment with placebo, but did not present a comparative assessment of the efficacy or safety of the biologics. In a published meta-analysis that compared the efficacy of anti-TNFs in 2009, infliximab showed significantly superior efficacy than other anti-TNFs. While in a head to head randomized trial compared to etanercept, ustekinumab achieved better outcomes. 13 However, a comparison between infliximab and ustekinumab has never been made, and hence there is a lack of knowledge and need for comparison of these two products in the literature. In 2009, the National Institute for Health and Clinical Excellence (NICE) 7 released a guidance document on the use of ustekinumab in the treatment of moderate-to-severe psoriasis that relied, in part, upon the results of an economic model that utilized data from a mixed treatment comparison of adalimumab, efalizumab, infliximab, and etanercept. However, the meta-analysis was not included in the guidance, and, to our knowledge, is not in the public domain. Recently, Reich et al 8 used a probit model to estimate the comparative efficacy and probability of response of all biologics approved for the treatment of plaque psoriasis in Europe. With updated clinical trial information and a different method, the objective of this study is to compare the efficacy of infliximab 5 mg/kg, ustekinumab 45 mg, and ustekinumab 90 mg for the treatment of moderate-to-severe psoriasis in adults who have plaque psoriasis and provide an estimate of the efficacy ranking for each comparator by conducting a mixed-treatment comparison (MTC) meta-analysis.
Materials and methods

Systematic literature search
A systematic search of the electronic database PubMed, from database inception to April 5, 2011 , was performed to identify evidence for inclusion in the meta-analysis. RCTs that reported the results of head-to-head or placebo-controlled comparisons of infliximab and ustekinumab were eligible for inclusion. Primary end points to measure efficacy of treatments included Psoriasis Area and Severity Index (PASI) 75 and PASI 90, while PASI 50 was not included. Studies must have provided baseline and end point, or baseline and change from baseline data (number or proportion of patients achieving PASI 75 or PASI 90 scores 14 ) and time of measurement (ie, weeks from baseline) for each outcome of interest. The search was limited to reports published in the English language (Table 1) .
Statistical analyses
To allow synthesis of both direct (head-to-head) and indirect evidence from available RCTs, Bayesian meta-analytic techniques 15 were used to perform an MTC meta-analysis. 16 Outcomes were analyzed as binary data using both fixedeffects and random-effects models. 15, 17 The log odds ratio (OR) was used as the measure of treatment effect. The likelihood of achieving a PASI 75 or PASI 90 response was estimated using the pooled estimate for placebo as the reference treatment.
Models were fitted with Markov chain Monte Carlo (MCMC) techniques using WinBUGS version 1.4.3; MRC Biostatistics Unit, Cambridge, UK. 18 Convergence was measured using the deviance information criterion (DIC), as proposed by Spiegelhalter et al. 19 For analyses that included multi-arm trials, a correlation structure was included in the models. Consistency between indirect and direct evidence was explored by comparing the results of traditional metaanalyses of head-to-head comparisons to those of the network meta-analysis. 20 MCMC sampling was used to estimate the probability of a treatment being superior to the others (ranking) using, as a proxy, the proportion of simulations where this situation was true.
Sensitivity analyses were conducted to explore the degree to which base case findings were affected by changes in methods, data from individual studies, or the choice of distributions for the vague priors, and stratifying patients by baseline PASI score.
Statistical heterogeneity was assessed using I 2 , the proportion of total variation in the estimates of treatment effect between studies. 21 Higher values of I 2 are evidence that a random effects model is preferable to a fixed effects model due to the heterogeneity present. 21 Due to the limited number of studies available for each comparison, the assessment of publication bias using funnel plots was not feasible.
Results
Systematic literature review
The literature search identified 34 studies, of which 12 were rejected: five were not RCTs, and seven did not report PASI 75 or PASI 90. Thus, 22 studies were available for potential inclusion in the review. Of those, 16 were excluded because they had an inappropriate outcome measure (n = 8); inappropriate study design (n = 2); were duplicate studies (n = 1); reported an inappropriate intervention (n = 1); included an inappropriate patient population (n = 3); or had a small sample size (#10) (n = 1) ( Figure 1 ). Thus, six studies, [22] [23] [24] [25] [26] [27] three for infliximab, 24, 25, 27 and three for ustekinumab 22, 23, 26 (Table 2) were included in the networks ( Figure 2 ).
Patients were between 35 and 46 years of age and there were slightly more males than females. All had plaque psoriasis with just less than 30% body surface area involvement. Disease duration ranged from 17 to 20 years, baseline PASI scores ranged from 19 to 22, and between 22% and 37% of patients had a diagnosis of psoriatic arthritis. All patients had previous exposure to disease-modifying antirheumatic agents, and less than 30% had received biologics at some time prior to study entry. A single study 27 reported that approximately 80% of patients had nail psoriasis. Individual study results are provided in Table 3 . Table 4 ). Of all treatments considered, infliximab 5 mg/kg had the greatest probability (95% in the fixed-effects model, and 92% in the random-effects model) of ranking as the most effective treatment for attaining a PASI 75. Ustekinumab 90 mg ranked second (95% in the fixed-effects model and 84% in the random-effects model), and ustekinumab 45 mg ranked third (99% in the fixed-effects model and 89% in the random-effects model). Placebo were the least submit your manuscript | www.dovepress.com
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Psoriasis mixed-treatment meta-analysis Notes: Comparison is for rows versus columns, eg, a greater proportion of patients will achieve PASI 75 with infliximab 5 mg/kg (row 2) than with placebo (column 1).
a CrIs are analogous to confidence intervals in frequentist statistics. Abbreviations: CrI, credible interval; PASI, psoriasis area and severity index.
effective, in both random-and fixed-effects models ( Table 5 ; Figure 3 ).
PASI 90: pooled estimates of treatment effect
Results from both the fixed-and random-effects models showed no statistically significant difference between infliximab 5 mg/kg and either of the two ustekinumab doses for the attainment of a PASI 90 response (OR = 0.56; 95% CrI: 0.10, 1.63 and OR = 0.63; 95% CrI: 0.07, 2.20, respectively, for infliximab 5 mg/kg versus ustekinumab 45 mg, and OR = 0.69; 95% CrI: 0.12, 2.00 and OR = 0.77; 95% CrI: 0.09, 2.70, respectively, for infliximab 5 mg/kg versus ustekinumab 90 mg). Consistent with the PASI 75 results, ustekinumab 90 mg was statistically significantly more effective than ustekinumab 45 mg in attaining a PASI 90 response in the fixed-effects model (OR = 1.22; 95% CrI: 1.01, 1.47), but not the random-effects model; however, it is unlikely that this difference is clinically significant ( Table 4 ). Infliximab 5 mg/kg had a probability of 80% in the fixed-effect model and 76% in the random-effects model of being the most effective treatment in attaining a PASI 90 response. Ustekinumab 90 mg had a probability of 79% and 62% of being ranked second in the fixed-and randomeffects models, respectively. Finally, ustekinumab 45 mg had probabilities of 86% and 67% of being ranked third in the fixed-and random-effects models, respectively (Table 5; Figure 3 ).
Consistency and comparisons between models
Results of the MTC MAs were consistent with those derived from traditional meta-analyses of infliximab versus placebo, ustekinumab 45 mg versus placebo, and ustekinumab 90 mg versus placebo, for both PASI 75 and PASI 90 measurements (Tables S1-S4).
A comparison of the results of MTC meta-analyses run with and without the correlation structure showed no appreciable differences (Table S5) .
DICs for the fixed-and random-effects models were comparable. For PASI 75, the DIC for the fixed-effects model was 91.089 compared to 91.744 for the random-effects models. The residual deviance values were 13.05 and 11.78, respectively. For PASI 90, the DIC was 94.692 and 92.052 for fixed-and random-effects models, respectively, and residual deviance values were 19.27 and 14.05, respectively. analysis to examine the effect of stratification of studies by mean baseline PASI score was not feasible.
Sensitivity analyses
Heterogeneity
Notable heterogeneity was observed for comparisons of placebo and either dose of ustekinumab for the PASI 90, and for comparisons between the ustekinumab dosages for both PASI 75 and PASI 90 (I 2 . 46%). Infliximab shows consistent treatment effects across studies for both the PASI 75 and PASI 90.
Discussion
The results of this MTC meta-analysis suggest that infliximab 5 mg/kg is likely to be more effective in attaining a PASI response than ustekinumab 90 mg or 45 mg in the treatment of moderate-to-severe psoriasis. Results from the fixed-and random-effects models found that infliximab had the greatest probability (92% and 95%, respectively) of ranking as the most effective treatment for attaining a PASI 75. Ustekinumab 90 mg had a probability of 95% and 84%, respectively, of ranking second, and ustekinumab 45 mg ranked third (99% and 89%, respectively). This result is similar to that of other published analyses that have included ustekinumab. 7, 8 Reich et al 8 estimated that infliximab had a probability of 93% being the most efficacious treatment in attaining a PASI 75; ustekinumab 90 mg a probability of 81% of ranking second; and ustekinumab 45 mg a probability of 79% of ranking third. In addition, they estimated that infliximab 5 mg/kg had the highest probability of achieving a PASI 50 (93%), PASI 75 (80%), and PASI 90 (55%) response, followed by ustekinumab 90 mg, ustekinumab 45 mg, adalimumab, etanercept, and efalizumab.
Overall, traditional and MTC meta-analytic estimates suggest that infliximab is likely to be the most efficacious of all the biologics for the treatment of psoriasis. These results, consistent with previous analyses, reinforced the efficacy of infliximab in psoriasis management. It is also confirmed that, although ustekinumab demonstrated statistically significant better outcomes than etanercept in one randomized clinical trial, this conclusion cannot be extended to the entire anti-TNF class. In addition, the ranking of the efficacy of all biologic therapies in psoriasis management will inform clinicians and policy makers about treatment and formulary decisions.
The main limitation of our MTC meta-analysis is the small number of RCTs available for inclusion in the networks. Thus, all estimates have wide confidence and credible intervals. However, analyses were based on the results of a systematic literature review, and it is unlikely that additional evidence on those comparators was available at the time of the search.
A search of the registry at ClinicalTrials.gov (http:// clinicaltrials.gov/) revealed that additional data is likely to be available in the future. As more research data becomes available on the efficacy of infliximab and ustekinumab, updated MTCs will produce more precise estimates. More precise estimates may also be possible if the networks are expanded by including other biologic treatments.
A second limitation is that there was no attempt to locate data from unpublished studies. Research with statistically significant results is more likely to be published than work with null or nonsignificant results (publication bias), which may lead to overly optimistic and incorrect results. 16 Third, RCTs included in the analyses reported outcomes at 10-12 weeks of therapy, and long-term outcomes were not available. This may be important, as plaque psoriasis is a chronic condition and biologics are likely to be prescribed on an ongoing basis. Notably, Reich et al 12 have reported that significant differences between biological treatments appear to be attenuated at 24 weeks' postinitiation of therapy.
Finally, the prescribing label of ustekinumab stipulates that patients weighing over 100 kg will be treated with 90 mg therapy, while patients under 100 kg of weight will take 45 mg. 28 In the clinical trials of ustekinumab, 29, 30, 31 however, the weight-based analyses were not reported, and it is therefore not possible to derive the results for the 45 mg and 90 mg ustekinumab for patients group with body weight under 100 kg or over 100 kg.
Conclusion
Based on this meta-analysis, patients with moderate-to-severe plaque psoriasis who are treated with infliximab 5 mg/kg are more likely than those treated with ustekinumab 90 mg and ustekinumab 45 to achieve a PASI 75 or PASI 90 response. 
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